ESR1 and breast neoplasm: This issue was tentatively addressed with the highly tumorigenic and moderately metastatic MDA-MB-231 cells [31], which show an ER-, PR-, Her2- immunoprofile, mimicking the condition that is characterized by a low response to chemotherapy and worst prognosis in breast tumor patients [32].